Related Experiment Video
Updated: Jun 4, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Contemporary epidemiology of metabolic dysfunction-associated steatotic liver disease
Do Han Kim1, Donghyun Ko2, Aijaz Ahmed3
1Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Introduction:
Metabolic dysfunction-associated steatotic liver disease (MASLD) is recognized as the most prevalent liver disease worldwide. Globally, it has impacted millions of individuals. With the recent change in terminology, MASLD is no longer a diagnosis of exclusion but rather a criterion-based diagnosis anchored around metabolic dysfunction. In addition to progressive liver fibrosis leading to cirrhosis, MASLD has been linked to extrahepatic complications, which include cardiovascular disease, non-liver-associated malignancies, and other adverse metabolic outcomes. Importantly, disease severity and prognosis are heterogeneous and are influenced by genetic susceptibility, environmental exposures, metabolic comorbidities, and behavioral risk factors.
Areas Covered:
This review provides a contemporary overview of the global incidence and prevalence of MASLD. In addition, it also summarizes recent temporal trends to predict future disease burden. Ultimately, this review seeks to clarify the evolving epidemiologic landscape of MASLD and highlight key gaps that must be addressed to inform effective prevention, surveillance, and health system planning.
Expert Opinion:
The rising prevalence of MASLD demands a shift from generic management to precision medicine. Since disease progression varies wildly based on genetics and metabolic profiles, future care must prioritize identifying high-risk phenotypes early. Without targeted interventions, the recognition of MASLD-related complications will be delayed.
Related Concept Videos
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Cirrhosis II: Pathophysiology
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can also...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...

